<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95774">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912456</url>
  </required_header>
  <id_info>
    <org_study_id>CSL830_3001</org_study_id>
    <secondary_id>2013-000916-10</secondary_id>
    <nct_id>NCT01912456</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <authority>Canada: Institutional Review Board</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing
      hereditary angioedema attacks when it is administered under the skin of subjects with
      hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each
      subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period
      and who are eligible will then enter the treatment phase which comprises two sequential
      treatment periods. In the treatment phase, subjects will be randomized to one of four arms
      consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment
      period and treatment with low- or higher-volume placebo in the other treatment period. The
      study will measure the number of hereditary angioedema attacks that subjects experience
      while receiving each treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The time-normalized number of hereditary angioedema attacks</measure>
    <time_frame>During the treatment phase, up to 32 weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a 50% reduction in the number of hereditary angioedema attacks</measure>
    <time_frame>During the treatment phase, up to 32 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of subjects with a 50% relative reduction in the time-normalized number of hereditary angioedema attacks during treatment with C1-esterase inhibitor  compared with placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of uses of rescue medication</measure>
    <time_frame>During the treatment phase, up to 32 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time-normalized number of uses of rescue medication during treatment with C1-esterase inhibitor or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with any adverse events</measure>
    <time_frame>During or within 24 hours of C1-esterase or placebo administration.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The percentage of subjects with any adverse events that begin within 24 hours of administration of C1-esterase inhibitor or placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hereditary Angioedema Types I and II</condition>
  <arm_group>
    <arm_group_label>Higher-volume placebo, then low-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-volume C1-esterase inhibitor, then higher-volume placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-volume placebo, then higher-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher-volume C1-esterase inhibitor, then low-volume placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-volume C1-esterase inhibitor</intervention_name>
    <arm_group_label>Higher-volume placebo, then low-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Low-volume C1-esterase inhibitor, then higher-volume placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Higher-volume C1-esterase inhibitor</intervention_name>
    <arm_group_label>Low-volume placebo, then higher-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Higher-volume C1-esterase inhibitor, then low-volume placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-volume placebo</intervention_name>
    <arm_group_label>Low-volume placebo, then higher-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Higher-volume C1-esterase inhibitor, then low-volume placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Higher-volume placebo</intervention_name>
    <arm_group_label>Higher-volume placebo, then low-volume C1-esterase inhibitor</arm_group_label>
    <arm_group_label>Low-volume C1-esterase inhibitor, then higher-volume placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Run-In Period Inclusion Criteria:

          -  Males or females aged 12 years or older.

          -  A clinical diagnosis of hereditary angioedema type I or II.

          -  Hereditary angioedema attacks over a consecutive 2-month period that required acute
             treatment, medical attention, or caused significant functional impairment.

        Eligibility Criteria for Entering Treatment Period 1:

          -  Laboratory confirmation of type I or type II hereditary angioedema, including
             C1-esterase inhibitor functional activity less than 50% AND C4 antigen level below
             the laboratory reference range.

          -  No clinically significant abnormalities as assessed using laboratory parameters.

          -  During participation in the run-in period, subjects must have experienced hereditary
             angioedema attacks that required acute treatment, required medical attention, or
             caused significant functional impairment.

        Exclusion Criteria:

        Run-In Period Exclusion Criteria:

          -  History of clinical significant arterial or venous thrombosis, or current history of
             a clinically significant prothrombotic risk.

          -  Incurable malignancies at screening.

          -  Any clinical condition that will interfere with the evaluation of C1-esterase
             inhibitor therapy.

          -  Clinically significant history of poor response to C1-esterase therapy for the
             management of hereditary angioedema.

          -  Receiving therapy prohibited by the protocol, including medications for hereditary
             angioedema prophylaxis.

          -  Female subjects who started taking or changed dose of any hormonal contraceptive
             regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing
             products) within 3 months prior to the screening visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registration Coordinator</last_name>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45267-0563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 11, 2014</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
    <mesh_term>Hereditary Angioedema Types I and II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1</mesh_term>
    <mesh_term>Complement C1s</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
